Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein |
Domain |
PF07686 Immunoglobulin V-set domain |
Function |
Functions as a receptor for the Fc fragment of IgA and IgM. Binds IgA and IgM with high affinity and mediates their endocytosis. May function in the immune response to microbes mediated by IgA and IgM. |
Biological Process |
GO:0002250 adaptive immune response |
Molecular Function | - |
Cellular Component | - |
KEGG | - |
Reactome |
R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-109582: Hemostasis |
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between FCAMR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of FCAMR in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of FCAMR in various data sets.
|
Points in the above scatter plot represent the mutation difference of FCAMR in various data sets.
|
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCAMR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCAMR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCAMR. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCAMR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of FCAMR expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between FCAMR and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | FCAMR |
Name | Fc receptor, IgA, IgM, high affinity |
Aliases | FKSG87; FCA/MR; CD351; Fc alpha/mu receptor; immunity related factor; receptor for Fc fragment of IgA and Ig ...... |
Chromosomal Location | 1q32.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting FCAMR collected from DrugBank database. |
There is no record. |